Immutep Limited (IMM)

A coveted ASCO spot for Efti

Announcement highlights

Immutep released their Appendix 4C today with operational update. Importantly Immutep announced this week they have secured a coveted oral presentation position at ASCO (American Society of Clinical Oncology) annual meeting in June (3-7th in Chicago), where they will report on updated results (interim) from their TACTI-002 Phase II trial of Efti in combination with Merck’s Keytruda as a 1st line therapy in advanced/metastatic non-small cell lung carcinoma (NSCLC). This is in addition to a poster presentation focused on interim data for their Phase Ib TACTI-003 trial in advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Further details will be made available including data with the abstract release on May 26th (5pm ET), Final data release will be during the ASCO meeting (June 3rd & June 6th).

Immutep finished 3Q22 with $87.2M net cash, which will support their ongoing clinical trial programs (TACTI-002, TACTI-003, INSIGHT) in addition to providing R&D capital for progression of their Phase III program in metastatic HR+/HER2- breast cancer (AIPAC-002). Immutep spent $8.13M on R&D during the quarter which included manufacturing spend for Efti and IMP761 to support clinical programs.

Wilson’s view

Initial analysis

Oral presentation at ASCO places TACTI-002 abstract within top ~5%. Winning a coveted oral presentation spot at ASCO, the world’s largest and most influential cancer conference is a win for Immutep and speaks to the interest levels in their NSCLC TACTI-002 data from the panel of assessing clinicians. It is our understanding there are only ~260 spots for oral presentations each meeting with ~6,200 applications (2019 ASCO data). Oral presentations are chosen for abstracts where the data is deemed to be highly relevant and interesting for attendees, with poster presentations rounding out a further 1,900 positions (~30% success rate).

ASCO the place to unveil key results with the entire pharma industry watching. ASCO is an event that is broadly attended by the clinical, as well as investment and pharmaceutical industries, with significant clinical data readsouts often unveiled at this annual meeting. ASCO is of intense focus for the pharmaceutical industry as this is where key data readouts are unveiled that often prompt deal making or partnerships. Whilst this is not Immutep’s first ASCO experience, their continued ability to be selected to present their data on this stage is supportive of their broadening industry exposure which is amplified given the recent BMS approval of anti-LAG-3 relatlimab in March.

NSCLC opportunity is ~50% of our valuation. Lung cancer is the second most abundant cancer globally with ~84% of lung cancers being NSCLC. Tobacco smoking has been a huge driver of NSCLC incidence with incredibly high mortality rates associated with metastatic disease (7% 5-year survival rate). Initial pembrolizumab (Keytruda) monotherapy approval in mNSCLC was granted in April 2019 which has now become standard of care, alongside other anti-PD-1 therapies including atezolizumab (anti-PD-L1) and nivolumab. Acquired resistance to these anti-PD-1/L1 therapies is a key issue the industry is attempting to combat with rates climbing north of 50% of patients by ~24months of therapy (Table 1).

Table 1. Acquired resistance rates to anti-PD-1/PD-L1 therapies in NSCLC is high

<table>
<thead>
<tr>
<th>Indication</th>
<th>Checkpoint inhibitor</th>
<th>Trial</th>
<th>Acquired resistance rate</th>
<th>Timeframe (median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC</td>
<td>Pembrolizumab</td>
<td>Keynote 001</td>
<td>41-57%</td>
<td>61 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Keynote 042</td>
<td>52%</td>
<td>24 months</td>
</tr>
<tr>
<td>Nivolumab</td>
<td></td>
<td>CheckMate 017, 057, 063, 003</td>
<td>64%</td>
<td>48 months</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td></td>
<td>OAK</td>
<td>55%</td>
<td>28 months</td>
</tr>
</tbody>
</table>

Source: Adapted from Schoenfeld & Hellmann1.

Acquired resistance renders these therapies effectively useless in half of the patient population after this period where they fall back to chemotherapy approaches which are often ineffective and/or toxic. We value the opportunity for Efti in NSCLC as being worth $0.53/share based on a licensing deal assessment which assumes peak royalty revenues of ~$350M and $470M in milestone payments. Our evaluation of potential peak sales for Efti in mNSCLC exceeds US$2.5B across US and EU5 markets.

**Expansion of a blockbuster’s addressable market.** We continue to view the opportunity for Efti as sizable given its ability to extend (efficacy) and expand (patient pool) the addressable market for anti-PD-1 blockbusters, i.e. pembrolizumab (Keytruda) with annual sales of US$17B in FY21. The ability for Efti to re-engage the immune system’s attack functions on tumours (effectively re-igniting the anti-tumoural effect of Keytruda) is key to our positive thesis, and in achieving this in a patient group that is not pre-selected for PD-L1 expression. As a reminder, current Keytruda approvals in 1st line mNSCLC only apply to ~65% of total patient pool in USA and ~30% total patient pool in Europe. Patients with high (≥50% TPS) or low (≥1% TPS) PD-L1 expression in their tumours are indicated for Keytruda therapy only (Figure 1). The TACTI-002 trial – including the data to be presented at ASCO on June 3rd – focuses on including this remaining 35% of patients with no detectable PD-L1 expression (≤1% PD-L1 TPS). Interim data thus far supports the premise that the addition of Efti can improve survival outcomes even in low PD-L1 expressing patients – this is the key to expanding Keytruda’s addressable market by >30%. The upcoming TACTI-002 readout should further develop this idea.

**Figure 1. Keytruda monotherapy approvals in mNSCLC (1st and 2nd line) based on PD-L1 tumour expression status.**

At present ~35% of mNSCLC patients are not addressed by Keytruda therapy – Efti could capture a portion of this segment.

**Earnings implications**

None.

**Investment view**

We maintain our OVERWEIGHT rating and $0.91 per share risked PT on Immutep. Our unrisked PT is $2.33 per share.
Disclaimers and Disclosures

Recommendation structure and other definitions

Analyst certification
Each analyst of Wilsons Advisory and Stockbroking Limited (ACN 010 529 665: AFSL 238375) ("Wilsons") whose name appears in this research certifies that (1) the recommendations and opinions expressed in this research accurately reflect the analyst’s personal, independent and objective views about any and all of the subject securities or issuers; (2) no part of the analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the analyst in the research; and (3) to the best of the analyst’s knowledge, he/she is not in receipt of material non-public information about the issuer.

Disclaimer
This document has been prepared by Wilsons. This communication is not to be disclosed in whole or part or used by any other party without Wilsons’ prior written consent. All material presented in this document, unless specifically indicated otherwise, is under copyright to Wilsons. None of the material, its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Wilsons. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Wilsons to any registration or licensing requirement within such jurisdiction.

This document is being supplied to you solely for your information and no action should be taken on the basis of or in reliance on this document. To the extent that any information prepared by Wilsons contains any financial product advice, it is general advice only and has been prepared by Wilsons without reference to your objectives, financial situation or needs. You should consider the appropriateness of the advice in light of your own objectives, financial situation and needs before following or relying on the advice. You should also obtain a copy of, and consider, any relevant disclosure document before making any decision to acquire a financial product. Please refer to Wilsons’ Financial Services Guide for more information: wilsonsadvisory.com.au/disclosures. Any person, before acting on any advice contained within this communication, should first consult with a Wilsons investment adviser to assess whether the advice within this communication is appropriate for their objectives, financial situation and needs. Those acting upon such information without advice do so entirely at their own risk.

This document provided by Wilsons is current as at the date of the issue but may be superseded by future publications. Wilsons assumes no obligation to update the information or advise on further developments relating to the company or companies covered in this document ("Companies") or relevant financial products. Wilsons has not independently verified all of the information given in this document which is provided at a point in time and may not contain all necessary information about the Companies. Wilsons makes no warranty, express or implied, concerning any information prepared by Wilsons. Wilsons expressly disclaims (1) any implied warranty of merchantability or (2) fitness for a particular purpose, including any warranty for the use or the results of the use of any information prepared by Wilsons with respect to their correctness, quality, accuracy, completeness, reliability, performance, timeliness, or continued availability. Wilsons’ research content should be viewed as an additional investment resource, not as your sole source of information. To the fullest extent permitted by law, Wilsons, its related bodies corporate and their respective officers, directors, employees or agents, disclaim any and all liabilities for any loss or damage howsoever arising in connection with the use of this document or its contents. Past performance does not necessarily indicate a financial product’s likely future performance.

This document may contain "forward-looking statements". Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies which are outside the control of Wilsons and are subject to change without notice (including but not limited to economic conditions, market volatility and company-specific fundamentals), and therefore may not be realised in the future.

This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever.

Regulatory disclosures
Wilsons restricts research analysts from trading in securities for which they write research. Other Wilsons employees may hold interests in the company, but none of those interests are material. Wilsons further advises that at the date of this report, neither Wilsons Advisory and Stockbroking Limited or Wilsons Corporate Finance Limited have any material interests in the company.

Wilsons contact
For more information please phone: 1300 655 015 or email: publications@wilsonsadvisory.com.au